FDA approves Teva’s Sabril generic version; says making generic drugs competitive is key part to reduce drug cost

Announcing the approval of Teva’s Sabril generic tablets, FDA Commissioner, Scott Gottlieb said that prioritizing the approval of generic drugs to compete with medicines that face little or no competition is the Agency’s key part of efforts to support access and reduce drug costs to patients.

Read more

Innovent Biologcs testing potential of sintilimab in combination with chemotherapy in ORIENT-16, a phase III trial, on gastric cancer patients

Innovent Biologics has started testing on patients its Tyvyt, fully human anti-PD-1 therapeutic monoclonal antibody, with generic name sintilimab injection, in combination with capecitabine and oxaliplatin, patients with advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (GC or GEJ).

Read more